phospho-NLRC4(Ser-533)抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using phospho-NLRC4(Ser-533) rat mAb against NIH/3T3 (1) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using phospho-NLRC4(Ser-533) rat mAb. Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using phospho-NLRC4(Ser-533) rat mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

The phospho-NLRC4(Ser-533) antibody is a specialized tool used to detect the phosphorylated form of NLRC4 (NLR family CARD domain-containing protein 4) at serine residue 533. NLRC4 is a key component of inflammasomes, multiprotein complexes that regulate innate immune responses by activating caspase-1 and promoting the secretion of pro-inflammatory cytokines like IL-1β and IL-18. Phosphorylation of NLRC4 at Ser-533 is a critical post-translational modification required for its activation. This modification facilitates conformational changes in NLRC4. enabling its oligomerization and subsequent assembly into the inflammasome complex upon detection of pathogenic signals, such as bacterial flagellin or type III secretion system components.

The antibody is widely used in research to study NLRC4 activation mechanisms, inflammasome regulation, and its role in diseases linked to dysregulated inflammation, including autoinflammatory disorders, bacterial infections, and cancer. It aids in identifying phosphorylation-dependent interactions and signaling pathways by techniques like Western blotting, immunoprecipitation, or immunofluorescence. Understanding Ser-533 phosphorylation provides insights into how NLRC4 inflammasomes balance immune defense and avoid excessive inflammation, which may inform therapeutic strategies targeting inflammasome-related pathologies.